In the Media - Starpharma

Starpharma (ASX:SPL) to relaunch VIRALEZE treatment in UK

Apr 1st, 2022

The Market Herald features Starpharma following its latest announcement related to the relaunch of VIRALEZE™ in the UK.

Active agent in Australian-developed nasal spray highly active against 'Omicron'

Mar 2nd, 2022

Australian biotechnology and life sciences media platform, BiotechDispatch, featured the news of Starpharma's latest announcement regarding SPL7013's virucidal activity against Omicron.

Starpharma’s (ASX:SPL) nasal spray outperforms competitors against Omicron variant

Mar 1st, 2022

"Starpharma’s (SPL) antiviral nasal spray has achieved a greater than 99.5 per cent reduction of virus infectivity against the Omicron variant of SARS-CoV-2." The Market Herald reports on Starpharma, following the company's latest announcement.

Starpharma (ASX:SPL) pens distribution deal in Saudi Arabia

Feb 3rd, 2022

The Market Herald reports on Starpharma's new partnership with Etqan & Nazahah for the sales and distribution of VIRALEZE™ in Saudi Arabia.

Starpharma’s (ASX:SPL) December quarter boosted by VIRALEZE success

Jan 28th, 2022

The Market Herald reports on Starpharma, following the release of the company's Quarterly Cashflow and Activities Report.

Australian homegrown COVID-19 pipeline shows signs of maturity

Jan 27th, 2022

Starpharma's CEO Dr Jackie Fairley was interviewed by BioWorld about the company's antiviral nasal spray VIRALEZE™.

Starpharma announces early orders following Vietnam distribution agreement

Dec 14th, 2021

BiotechDispatch report on Starpharma's latest announcement related to the launch of VIRALEZE™ in Vietnam.

Starpharma (ASX:SPL) tables $2m in Vietnam VIRALEZE orders

Dec 13th, 2021

"Since October, pharmaceutical company Starpharma (SPL) has received VIRALEZE orders totaling more than $2 million for Vietnam", as reported in The Market Herald.

Novel Cabazitaxel Formulation Shows Promise for Metastatic Prostate Cancer

Nov 30th, 2021

Targeted Oncology features Starpharma's latest DEP® announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel.

Starpharma reports positive interim results from Phase 2 DEP cabazitaxel study in prostate cancer

Nov 27th, 2021

Starpharma's positive interim results from its ongoing phase 2 trial of DEP cabazitaxel featured in Seeking Alpha.

Starpharma Releases Positive DEP® Phase 2 Interim Results In Prostate Cancer

Nov 27th, 2021

British Herald reports on Starpharma's announcement, regarding the positive interim results from the prostate cancer cohort in its ongoing phase 2 trial of DEP^® cabazitaxel.

Starpharma Announces Encouraging Interim Results for Prostate Cancer Drug

Nov 27th, 2021

Gene Online reports on the news of Starpharma's latest announcement - the release of positive interim results from the prostate cancer cohort of Starpharma's ongoing phase 2 trial of DEP® cabazitaxel.

Starpharma (ASX:SPL) continues VIRALEZE success in December quarter

Oct 29th, 2021

"Starpharma (SPL) has released its September quarterly report, with the quarter again highlighted by the continued success of VIRALEZE," as reported by The Market Herald.

Starpharma signs distribution agreement for antiviral in Vietnam

Oct 26th, 2021

News of Starpharma signing an initial supply contract for VIRALEZE™ in Vietnam featured in BiotechDispatch. Read the article here.

Starpharma (ASX:SPL) signs VIRALEZE supply deal for Vietnam

Oct 26th, 2021

The Market Herald features news of Starpharma's latest supply arrangement for VIRALEZE™ in Vietnam.

Nanotechnology Offers New Ways To Fight An Endless Pandemic

Oct 18th, 2021

Starpharma's VIRALEZE™ antiviral nasal spray was featured in Report Wire.

Nanotechnology offers alternative ways to fight COVID-19 pandemic with antivirals

Oct 14th, 2021

Starpharma's VIRALEZE™ antiviral nasal spray was featured in the October issue (VOL 39) of Nature Biotechnology.

Starpharma (ASX:SPL) launches nasal spray into Italian market

Oct 8th, 2021

The Market Herald features news of Starpharma's latest distribution agreement for VIRALEZE™ antiviral nasal spray in Italy.

Starpharma (ASX:SPL) shows 99.99pc antiviral activity against Delta COVID-19 variant

Jul 27th, 2021

"Starpharma's (SPL) SPL7013 drug has shown a reduction of more than 99.99 per cent against the Delta variant of SARS-CoV-2," The Market Herald reports. Read the full article here. Read More

COVID-19: Viraleze Nasal Spray Highly Effective Against Alpha, Beta And Gamma Variants

Jun 19th, 2021

"New data released on June 18 showed that Australia’s Viraleze anti-COVID nasal spray is more than 99.99 per cent effective against three of the four variants of the SARS-CoV-2 virus," as reported by Republic World. Read the full article here.